Pharmacokinetic Studies on Some Novel (2-Nitro-1-Imidazolyl) Propanolamine Radiosensitizers
One area of current interest in radiosensitizer development is in the use of nitroimidazoles of a more polar nature than misonida-zole, combining the benefits of a shorter half-life, and thus reduced tissue exposure, which has been correlated with the neuropathy observed with misonidazole (1), while also minimising brain penetration through the blood-brain barrier (2). In the Gray Laboratory development programme, one aim has been to attempt to combine the advantages of a highly polar compound with an increased radiosensi-tizing efficiency by including basic functions in the 2-nitroimida-zole side chain. Preliminary data for one of these, the propanol-amine Ro 03–8799, indicating favourable pharmacokinetic properties following intraperitoneal administration have already been published (3).
KeywordsPharmacokinetic Study Polar Compound Intraperitoneal Administration Hypoxic Cell Polar Nature
Unable to display preview. Download preview PDF.